RxDoctor Payments Data

Christopher Cooper

Pulmonary Disease · Los Angeles, CANPI 1588680482

Payments from drug & device makers

$238,596in general payments, 2019–2025

Across 68 payments — averaging $3508.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$139K
  • GSK$56K
  • Medical Graphics Corporation$29K
  • Pulmonx Corporation$11K
  • Amgen$3K
  • Chiesi USA, Inc.$713
  • plus $47 from 2 others
$35,590in research payments, 2019–2025

Across 8 payments — averaging $4448.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$20K
  • Amgen$16K

What the payments were for

  • Consulting fees$222,99193%
  • Speaking & faculty fees$5,1502%
  • Travel & lodging$8,0763%
  • Food & beverage$1,5281%
  • Gifts$8510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited28$138,709
GSK24$56,034
Medical Graphics Corporation6$29,450
Pulmonx Corporation5$11,078
Amgen2$2,567
Chiesi USA, Inc.1$713
Boehringer Ingelheim1$33
AbbVie1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$238,596 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Other pulmonary disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →